Yüklüyor......
Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis
The development of FLT3-targeted inhibitors represents an important paradigm shift in the management of patients with highly aggressive fms-like tyrosine kinase 3-mutated (FLT3-mut) acute myeloid leukemia (AML). Midostaurin is an orally administered type III tyrosine kinase inhibitor which in additi...
Kaydedildi:
| Yayımlandı: | Ther Adv Hematol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5639976/ https://ncbi.nlm.nih.gov/pubmed/29051803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620717721459 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|